Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Citi"

727 News Found

Zydus receives final and tentative approval from USFDA for Tofacitinib Tablets
Drug Approval | March 22, 2023

Zydus receives final and tentative approval from USFDA for Tofacitinib Tablets

Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)


4.4 crore health records of citizens digitized and linked with ABHA
Digitisation | December 20, 2022

4.4 crore health records of citizens digitized and linked with ABHA

This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country


India is dedicated to ensure health Security for every citizen: Mandaviya
Policy | June 08, 2022

India is dedicated to ensure health Security for every citizen: Mandaviya

States have an important role in ensuring food safety and healthy food practices.


Mental wellness startup Lissun targets phygital presence in over 25 cities this year
Startup | May 18, 2022

Mental wellness startup Lissun targets phygital presence in over 25 cities this year

The centres will be located in Tier I and Tier II cities


New two-year Deucravacitinib data show promising results for severe plaque psoriasis
Biotech | May 12, 2022

New two-year Deucravacitinib data show promising results for severe plaque psoriasis

Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease


USFDA approves CITI Biopharma’s Vonjo
Drug Approval | March 01, 2022

USFDA approves CITI Biopharma’s Vonjo

Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients


U.S. FDA accepts Bristol Myers Squibb’s application for Deucravacitinib
Biotech | November 30, 2021

U.S. FDA accepts Bristol Myers Squibb’s application for Deucravacitinib

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.


Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
Drug Approval | September 01, 2021

Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab

JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis


NATCO signs licensing agreement with Lilly for Baricitinib
News | May 18, 2021

NATCO signs licensing agreement with Lilly for Baricitinib

Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India